These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11927094)

  • 21. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 22. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
    Carbonell-Estrany X; Simões EA; Dagan R; Hall CB; Harris B; Hultquist M; Connor EM; Losonsky GA;
    Pediatrics; 2010 Jan; 125(1):e35-51. PubMed ID: 20008423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab.
    Meissner HC; Anderson LJ; Pickering LK
    Pediatrics; 2004 Oct; 114(4):1082-4. PubMed ID: 15466107
    [No Abstract]   [Full Text] [Related]  

  • 24. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
    Manzoni P; Leonessa M; Farina D; Gomirato G
    Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
    [No Abstract]   [Full Text] [Related]  

  • 26. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health economics and RSV.
    Carbonell-Estrany X; Lázaro y de Mercado P
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A health care management company's experience with palivizumab--1 year later.
    Silverman W
    Manag Care; 2003 May; 12(5):49-50. PubMed ID: 12800748
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M; Lebmeier M; Wittenberg W
    J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential impact of palivizumab on pediatric airway reconstruction.
    Emerick K; Cunningham M; Hartnick C
    Am J Otolaryngol; 2006; 27(1):9-12. PubMed ID: 16360816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society].
    Chantepie A;
    Arch Pediatr; 2004 Nov; 11(11):1402-5. PubMed ID: 15519844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A health care management company's experience with palivizumab.
    Silverman W
    Manag Care; 2002 Jan; 11(1):45-6. PubMed ID: 11828875
    [No Abstract]   [Full Text] [Related]  

  • 37. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
    Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza
    An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recommendations for the prevention of respiratory syncytial virus infections. Standards Committee of the Spanish Society of Neonatology. Board of Directors of the Spanish Society of Neonatology].
    Carbonell Estrany X; Quero Jiménez J
    An Esp Pediatr; 2000 Apr; 52(4):372-4. PubMed ID: 11006170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.